Unified AMP PD Cohorts

The foundation of AMP PD is predicated on Parkinson’s disease (PD) related study data that is collected,AMPPDVennD harmonized, and made accessible for identifying new biomarkers and developing new treatments for PD. Overcoming challenges associated with resources, time and cost, and data availability is made possible through the collective efforts of the Michael J. Fox Foundation (MJFF) and National Institutes of Neurological Disorders and Stroke (NINDS) BioFIND study, Harvard Biomarkers Study (HBS), the NIA International Lewy Body Dementia Genetics Consortium Genome Sequencing in Lewy body dementia case-control cohort (LBD), the MJFF LRRK2 Cohort Consortium (LCC), the NINDS Parkinson's disease Biomarkers Program (PDBP), MJFF Parkinson’s Progression Markers Initiative (PPMI), and the NINDS Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease, Phase 3 (STEADY-PD3).

When unified, data from these seven cohorts offer the PD research community unprecedented access to a large, harmonized dataset with common clinical and genomic data, bridging the gap between prohibitive individual research constraints with large-scale, state-of-the art analysis.


    Introduction to the Cohorts


    An observational, cross-sectional, and multi-center study of biomarkers in moderate to advanced PD and control subjects.


    A powerful incubator for biomarker discovery and precision neurology that can speed up the biomarker test cycle from years to weeks.


    Developed to accelerate the discovery of promising new diagnostic and progression biomarkers for Parkinson's disease.


    Longitudinal study, contributing comprehensive clinical and imaging data and biological samples to the research community.

    Accessory Cohorts


    Evaluation on the efficacy of isradipine to slow progression of disability in early PD


    To determine the safety and tolerability of inosine and its ability to raise urate levels in blood and cerebral spinal fluid in individuals with early PD.



    Coming Soon...

    Unified cohorts - key selection criteria


    Cohort Data & Genetic Criteria

    All AMP PD Cohorts provided clinical data and at least one set of DNA, RNA, and Proteomic assay data. The following criteria was used to assess each of the four Cohorts and provides additional details for why each was selected and found suitable for inclusion:

    • Relevance to PD research
    • Dataset size (cases and controls)
    • Patient consent includes approval for broad data-sharing of de-identified clinical and molecular data
    • Adherence to the AMP PD DUC
    • Longitudinal study method
    • Uniform and standardized clinical data collection instruments
    • Biosample availability with quality control metrics
    • Inclusive of pathological sample data
    • Cost-benefit analysis regarding storage, data harmonization, and analytical costs is in the interest of the AMP PD community

    Cohort inclusion priorities and mission alignment